The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

IMvigor 210 Results in Metastatic Urothelial Carcinoma

Arjun V. Balar, MD
Published Online: 7:47 PM, Tue June 7, 2016
Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab (Tecentriq) as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma, as well as the impact of the FDA approval of atezolizumab for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.